Oncology has long been pharma’s biggest bucket for R&D, with investment historically leading to some of pharma’s most impactful breakthroughs.
In the coming years, innovations such as radiopharmaceuticals, new immunotherapies, and next-generation cell and gene therapies offer cutting-edge solutions in cancer care.
Included in this Trendline:
- Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach
- Too much of a good thing? A flood of data is slowing clinical trials.
- Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Offered Free by: PharmaVoice and Covaris
See All Resources from: PharmaVoice and Covaris
